Bristol Myers Squibb posted much better-than-expected second-quarter results on Wednesday on strong sales of its most ...

Cobenfy is one of the key products Bristol is counting on to take up the slack as patents on three of its top-selling drugs ...

In the cutthroat pharmaceutical arena, Pfizer stands poised for a strategic pivot and a potential earnings bonanza in 2025.